Learn what Marfan syndrome is and the role of stem cells in discovering a new way to treat this condition.
In this article:
Top 37 Twitter Accounts About Stem Cells
In a USA Today article, Rem Rieder discusses how Twitter acts as a “conveyor belt” for first-rate journalism, bringing to your attention news that you might otherwise miss. He points out that Twitter is a news pipeline for more than 200 million active users, often breaking news before it’s actually news.
Today, more and more people are looking to social media for their news. Because of Twitter’s short word count, it is a fast, effective, and to-the-point method of consuming stem cell news. Especially for stem cell news, Twitter is an indispensable resource. [Read more…]
Axol Bioscience signs exclusive agreement with The Francis Crick Institute to license iPSC technology
Today, The Francis Crick Institute signed an agreement giving Axol Bioscience exclusive rights to a methodology to generate human pluripotent stem cell (hPSC) derived cells used in drug screening and cardiotoxicity assays.
The technology developed by the Crick is used to generate near-homogeneous populations of hPSC derived left ventricular cardiomyocytes (LVCMs) with improved structural, functional and metabolic maturity. The initial discovery was protected, funded and further developed towards commercial application in-house at the Crick. This work has just been published in Cell Reports Methods and the intellectual property has been licensed to Axol Bioscience for both the production and supply of LVCMs, as well as the provision of screening services. [Read more…]
PBS Biotech and denovoMATRIX Join Forces to Boost Manufacturing Processes for Cell & Gene Therapies
Camarillo, CA (April 11, 2023) – PBS Biotech, an innovative, single-use bioreactor manufacturer and process development services provider, announces its collaboration with denovoMATRIX, a leading supplier of next-gen biomimetic coating technologies. By joining forces, PBS Biotech and denovoMATRIX seek to foster xeno-free expansion and scale-up of clinical-grade mesenchymal stromal cells (MSCs) and induced pluripotent stem cells (iPSCs) for use in allogeneic and autologous cell and gene therapies. The first outcome of this collaboration is a white paper presenting the advantages in MSC manufacturing that can be achieved using their cutting-edge technologies. [Read more…]
Tempo Bioscience Expands Human Liver Models for Toxicity Evaluation and Disease Modeling
SAN FRANCISCO–Tempo Bioscience, Inc. (“Tempo”), a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories: [Read more…]
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 201
- Next Page »